Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of PMF, PPV MF or PET-MF, irrespective of JAK2 mutational status according to the 2008 revised International Standard Criteria~* Peripheral blast count \< 10%~* Requires therapy for MF in the opinion of the investigator~* Received prior monotherapy treatment with ruxolitinib for at least 12 consecutive weeks and experienced treatment interruption because of lossof response or adverse event~* Patients adhering to the Screening phase assessments and undergoing a a ruxolitinib-free washout period of a minimum of 1 week and a maximum of 8 weeks~* ECOG performance status 0, 1, 2, or 3~* Adequate bone marrow function~* Written informed consent~Exclusion Criteria:~* Patients not initially responding (primary resistance) to ruxolitinib therapy~* Patients who underwent a splenectomy or spleen radiation~* Patients currently scheduled for bone marrow transplant~* Patients who have discontinued ruxolitinib \< 14 days prior to screening~* Patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg total daily dose~* Leukemic transformation~* Inadequate renal function~* Presence of clinically meaningful active bacterial, fungal, parasitic or viral infection which requires therapy~* Previous history of Progressive Multifocal Leuko-encephalopathy (PML)~* Clinically significant cardiac disease or significant concurrent medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): All participants received ruxolitinib.

Based on this trial design, predict the completion outcome and termination type (if applicable).